HAM
Hedges Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.2M | Sell |
24,700
-4,650
| -16% | -$226K | 0.97% | 36 |
|
|
2025
Q1 | $999K | Buy |
29,350
+5,000
| +21% | +$170K | 0.66% | 56 |
|
|
2024
Q4 | $958K | Buy |
24,350
+1,200
| +5% | +$47.2K | 0.63% | 55 |
|
|
2024
Q3 | $1.09M | Buy |
23,150
+1,350
| +6% | +$63.4K | 0.72% | 49 |
|
|
2024
Q2 | $1.18M | Buy |
21,800
+2,425
| +13% | +$131K | 0.85% | 42 |
|
|
2024
Q1 | $1.32M | Sell |
19,375
-2,000
| -9% | -$136K | 0.93% | 39 |
|
|
2023
Q4 | $1.34M | Sell |
21,375
-1,150
| -5% | -$72K | 1.05% | 33 |
|
|
2023
Q3 | $1.02M | Buy |
22,525
+3,575
| +19% | +$162K | 0.89% | 37 |
|
|
2023
Q2 | $1.06M | Buy |
18,950
+2,650
| +16% | +$149K | 0.9% | 37 |
|
|
2023
Q1 | $737K | Buy |
16,300
+625
| +4% | +$28.3K | 0.63% | 48 |
|
|
2022
Q4 | $637K | Buy |
15,675
+5,200
| +50% | +$211K | 0.57% | 47 |
|
|
2022
Q3 | $685K | Sell |
10,475
-1,900
| -15% | -$124K | 0.68% | 46 |
|
|
2022
Q2 | $753K | Buy |
12,375
+2,600
| +27% | +$158K | 0.71% | 43 |
|
|
2022
Q1 | $614K | Buy |
9,775
+1,425
| +17% | +$89.5K | 0.48% | 61 |
|
|
2021
Q4 | $633K | Buy |
+8,350
| New | +$633K | 0.49% | 60 |
|